Trial Profile
A Phase I, Randomised, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4831 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitiperstat (Primary)
- Indications Heart failure
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 07 Jan 2019 Results (n=40) evaluating safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in healthy volunteers published in the British Journal of Clinical Pharmacology
- 05 Jan 2017 Status changed from suspended to discontinued.
- 09 Nov 2016 Status changed from recruiting to suspended.